Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease

The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.

This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.

Inclusion Criteria:

• At least 18 years of age.
• Metastatic disease.
• One previous treatment including docetaxel (Taxotere).
• At least 3 weeks since last surgery/radiation/chemotherapy
• ECOG Performance Status of 0, 1 or 2

Exclusion Criteria:

• Active brain metastases